PD-L1 Immunotherapy shrinks tumors in Bladder Cancer Patients

被引：0
|
作者：
不详
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2015年 / 11卷 / 09期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：2120 / 2120
页数：1
相关论文
共 50 条
  • [41] Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy
    Qiu, Qingqing
    Li, Jieyi
    Chen, Qiaofeng
    Zhao, Xiaokai
    Zhou, Ru
    Zhang, Wenpeng
    Gong, Ziying
    Zhang, Daoyun
    Wang, Mingliang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] PD-L1 Expression in Uterine Smooth Muscle Tumors: Implications for Immunotherapy
    Shanes, Elisheva
    Mills, Anne
    MODERN PATHOLOGY, 2019, 32
  • [43] PD-L1 Expression in Uterine Smooth Muscle Tumors: Implications for Immunotherapy
    Shanes, Elisheva
    Mills, Anne
    LABORATORY INVESTIGATION, 2019, 99
  • [44] PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
    Ren, Xiaohui
    Wang, Lijuan
    Liu, Likun
    Liu, Juan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [45] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911
  • [46] PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors
    Tykodi, Scott S.
    Brahmer, Julie R.
    Hwu, Wen-Jen
    Chow, Laura Q.
    Topalian, Suzanne Louise
    Hwu, Patrick
    Odunsi, Kunle
    Camacho, Luis H.
    Kauh, John S.
    Pitot, Henry Clement
    Hamid, Omid
    Pardoll, Drew M.
    Agrawal, Shruti
    Parker, Susan
    Goldberg, Stacie
    Gupta, Ashok Kumar
    Wigginton, Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Jiao, Zhongyu
    Zhang, Jun
    CARCINOGENESIS, 2023, 44 (12) : 795 - 808
  • [48] Blocking of the PD-1/PD-L1 interaction by an affinity peptide for cancer immunotherapy
    Luo, H.
    Li, X.
    Zhu, N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1782 - 1782
  • [49] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Jiang, Yongshuai
    Chen, Ming
    Nie, Hong
    Yuan, Yuanyang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1111 - 1122
  • [50] Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
    Wang, Fengling
    Ye, Wenling
    Wang, Shuang
    He, Yongxing
    Zhong, Haiyang
    Wang, Yuwei
    Zhu, Yongchang
    Han, Jianting
    Bing, Zhitong
    Ji, Shaoping
    Liu, Huanxiang
    Yao, Xiaojun
    NEOPLASIA, 2021, 23 (03): : 281 - 293
12345